184 related articles for article (PubMed ID: 2009366)
1. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia.
Bacigalupo A; Van Lint MT; Occhini D; Gualandi F; Lamparelli T; Sogno G; Tedone E; Frassoni F; Tong J; Marmont AM
Blood; 1991 Apr; 77(7):1423-8. PubMed ID: 2009366
[TBL] [Abstract][Full Text] [Related]
2. Total-body irradiation before bone marrow transplantation for acute leukemia in first or second complete remission. Results and prognostic factors in 326 consecutive patients.
Belkacémi Y; Pène F; Touboul E; Rio B; Leblond V; Gorin NC; Laugier A; Gemici C; Housset M; Ozsahin M
Strahlenther Onkol; 1998 Feb; 174(2):92-104. PubMed ID: 9487372
[TBL] [Abstract][Full Text] [Related]
3. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation.
Bacigalupo A; Vitale V; Corvò R; Barra S; Lamparelli T; Gualandi F; Mordini N; Berisso G; Bregante S; Raiola AM; Van Lint MT; Frassoni F
Br J Haematol; 2000 Jan; 108(1):99-104. PubMed ID: 10651732
[TBL] [Abstract][Full Text] [Related]
4. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).
Frassoni F; Labopin M; Gluckman E; Prentice HG; Vernant JP; Zwaan F; Granena A; Gahrton G; De Witte T; Gratwohl A; Reiffers J; Gorin NC
Bone Marrow Transplant; 1996 Jan; 17(1):13-8. PubMed ID: 8673048
[TBL] [Abstract][Full Text] [Related]
5. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A
Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic bone marrow transplantation in children with acute myelogenous leukemia in first remission. Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) and the Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO).
Dini G; Boni L; Abla O; Uderzo C; Polchi P; Locatelli F; Di Bartolomeo P; Arcese W; Iori AP; Rossetti F
Bone Marrow Transplant; 1994 Jun; 13(6):771-6. PubMed ID: 7920313
[TBL] [Abstract][Full Text] [Related]
9. Total body irradiation correlates with chronic graft versus host disease and affects prognosis of patients with acute lymphoblastic leukemia receiving an HLA identical allogeneic bone marrow transplant.
Corvò R; Paoli G; Barra S; Bacigalupo A; Van Lint MT; Franzone P; Frassoni F; Scarpati D; Bacigalupo A; Vitale V
Int J Radiat Oncol Biol Phys; 1999 Feb; 43(3):497-503. PubMed ID: 10078628
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S
Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189
[TBL] [Abstract][Full Text] [Related]
11. High incidence of early leukemic relapse in patients given cyclosporin and T cell depleted HLA-identical sibling marrow transplants for acute leukemia in first remission.
Atkinson K; Biggs J; Dodds A; Concannon A; Downs K; Ashby M; McKenzie IF
Aust N Z J Med; 1988 Jun; 18(4):587-93. PubMed ID: 3058104
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission: the effect of FAB classification and GVHD prophylaxis.
Fagioli F; Bacigalupo A; Frassoni F; Van Lint MT; Occhini D; Gualandi F; Lamparelli T; Clavio M; Vitale V; Sogno G
Bone Marrow Transplant; 1994 Mar; 13(3):247-52. PubMed ID: 8199567
[TBL] [Abstract][Full Text] [Related]
13. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide.
Essell JH; Thompson JM; Harman GS; Halvorson RD; Snyder MJ; Johnson RA; Rubinsak JR
Blood; 1992 May; 79(10):2784-8. PubMed ID: 1586725
[TBL] [Abstract][Full Text] [Related]
14. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival.
Doney K; Fisher LD; Appelbaum FR; Buckner CD; Storb R; Singer J; Fefer A; Anasetti C; Beatty P; Bensinger W
Bone Marrow Transplant; 1991 Jun; 7(6):453-9. PubMed ID: 1873592
[TBL] [Abstract][Full Text] [Related]
15. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation.
Van Lint MT; Uderzo C; Locasciulli A; Majolino I; Scimé R; Locatelli F; Giorgiani G; Arcese W; Iori AP; Falda M; Bosi A; Miniero R; Alessandrino P; Dini G; Rotoli B; Bacigalupo A
Blood; 1998 Oct; 92(7):2288-93. PubMed ID: 9746766
[TBL] [Abstract][Full Text] [Related]
16. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
Carlens S; Ringdén O; Aschan J; Hägglund H; Ljungman P; Mattsson J; Remberger M
Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: factors predictive of survival, relapse and graft-versus-host disease.
Moussalem M; Esperou Bourdeau H; Devergie A; Baruchel A; Ribaud P; Socie G; Parquet N; Traineau R; Hirsch I; Schaison G
Bone Marrow Transplant; 1995 Jun; 15(6):943-7. PubMed ID: 7581095
[TBL] [Abstract][Full Text] [Related]
18. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study.
Dopfer R; Henze G; Bender-Götze C; Ebell W; Ehninger G; Friedrich W; Gadner H; Klingebiel T; Peters C; Riehm H
Blood; 1991 Nov; 78(10):2780-4. PubMed ID: 1824271
[TBL] [Abstract][Full Text] [Related]
20. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone.
Nademanee A; Schmidt GM; Parker P; Dagis AC; Stein A; Snyder DS; O'Donnell M; Smith EP; Stepan DE; Molina A
Blood; 1995 Aug; 86(3):1228-34. PubMed ID: 7620176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
